{"body": "Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) 69.1% LOWER; announced top-line safety and efficacy results for Part B of the MoveDMDÂ® trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy (DMD).\n\nOverstock.com (NASDAQ: OSTK) 13.8% HIGHER; reported Q4 EPS of $0.12, $0.16 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $526.2 million versus the consensus estimate of $523 million.\n\nSynergy Pharmaceuticals Inc. (Nasdaq: SGYP) 12.7% LOWER; announced an agreement to sell $125 million of its common stock to an underwriting syndicate led by Cantor Fitzgerald & Co., in a registered underwritten public offering.\n\nBoot Barn Holdings (NYSE: BOOT) 10% LOWER; reported Q3 EPS of $0.37, $0.02 worse than the analyst estimate of $0.39. Revenue for the quarter came in at $199.4 million versus the consensus estimate of $201.98 million. GUIDANCE: Boot Barn Holdings sees Q4 2017 EPS of $0.17-$0.20, versus the consensus of $0.23. Boot Barn Holdings sees FY2017 EPS of $0.60-$0.63, versus the consensus of $0.66.\n\nXOMA Corporation (Nasdaq: XOMA) 9.6% HIGHER; announced today that it has established proof-of-concept for its product candidate 358 in congenital hyperinsulinism (CHI) and hypoglycemia post-bariatric surgery (PBS). The Company will host a webcast and conference call today, January 31, 2017, at 2:00 p.m. PST (5:00 p.m. EST) to share data from these studies. The CHI acute studies have met their objectives of establishing initial safety and 358 proof-of-concept in CHI patients aged 12 and up across several dosing levels. The Company is nearing the launch of a multi-dose study in children with CHI aged 2 and up that will be conducted in the United Kingdom. The PBS study has completed dosing in the single-dose cohorts and has also met its objectives; a multi-dose study has been initiated.\n\nMatch Group (NASDAQ: MTCH) 5.9% LOWER; reported Q4 EPS of $0.29, $0.05 better than the analyst estimate of $0.24. Revenue for the quarter came in at $319.7 million versus the consensus estimate of $320.62 million.\n\nManhattan Associates, Inc. (NASDAQ: MANH) 4.4% LOWER; reported Q4 EPS of $0.46, $0.03 better than the analyst estimate of $0.43. Revenue for the quarter came in at $147.6 million versus the consensus estimate of $149.83 million. GUIDANCE: Manhattan Associates, Inc. sees FY2017 EPS of $1.89-$1.93, versus the consensus of $2.02. Manhattan Associates, Inc. sees FY2017 revenue of $622-632 million, versus the consensus of $657.63 million.\n\nApple (NASDAQ: AAPL) 3.3% HIGHER; reported Q1 EPS of $3.36, $0.14 better than the analyst estimate of $3.22. Revenue for the quarter came in at $78.4 billion versus the consensus estimate of $77.38 billion.\n\nAdvanced Micro Devices (NASDAQ: AMD) 3.2% HIGHER; reported Q4 EPS of ($0.01), $0.01 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.07 billion.\n\nSanchez Energy Corporation (NYSE: SN) 3.1% LOWER; intends to commence an underwritten public offering of 10,000,000 shares of the Company's common stock. The Company expects to grant the underwriter a 30-day option to purchase up to an additional 1,500,000 shares of its common stock. The Company intends to use the net proceeds from this offering for general corporate purposes including working capital.\n\nCarbonite, Inc. (NASDAQ: CARB) 2.9% HIGHER; acquired Double-Take Software, an affiliate of Vision Solutions, Inc. and Clearlake Capital. The acquisition enhances Carbonites existing suite of data protection solutions for small and midsize businesses (SMB) with high availability technology that significantly minimizes downtime. Carbonite also announced preliminary fourth quarter and full year 2016 financial results.\n\nAlign Technology (NASDAQ: ALGN) 1.7% HIGHER; reported Q4 EPS of $0.59, $0.07 worse than the analyst estimate of $0.66. Revenue for the quarter came in at $293.2 million versus the consensus estimate of $292.4 million. GUIDANCE: Align Technology sees Q1 2017 EPS of $0.64-$0.67, versus the consensus of $0.63. Align Technology sees Q1 2017 revenue of $295-298 million, versus the consensus of $293.5 million.\n\nIllumina (NASDAQ: ILMN) 1% LOWER; reported Q4 EPS of $0.85, $0.03 better than the analyst estimate of $0.82. Revenue for the quarter came in at $619 million versus the consensus estimate of $616.41 million. GUIDANCE: Illumina sees FY2017 EPS of $3.60-$3.70, versus the consensus of $3.65. projecting 10% to 12% revenue growth. Illumina sees Q1 2017 EPS of $0.60-$0.65, versus the consensus of $0.79. Q1 revenue is seen at $580-$595 vs consensus of $615.3 million.", "category": "Apple Inc 1-31-17", "title": "After-Hours Stock Movers 01/31: (OSTK) (XOMA) (AAPL) Higher; (CATB) (SGYP) (BOOT) Lower (more...)"}